471 related articles for article (PubMed ID: 18760876)
1. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
Lin CY; Chuang TF; Liao KW; Huang YJ; Pai CC; Chu RM
Cancer Lett; 2008 Dec; 272(2):285-95. PubMed ID: 18760876
[TBL] [Abstract][Full Text] [Related]
2. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
4. Depletion of IL-10- and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells.
Seo N; Tokura Y; Takigawa M; Egawa K
J Immunol; 1999 Jul; 163(1):242-9. PubMed ID: 10384122
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
6. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
7. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
8. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
9. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-10 reduces natural killer (NK) sensitivity of tumor cells by downregulating NK target structure expression.
Tsuruma T; Yagihashi A; Hirata K; Torigoe T; Araya J; Watanabe N; Sato N
Cell Immunol; 1999 Dec; 198(2):103-10. PubMed ID: 10648124
[TBL] [Abstract][Full Text] [Related]
11. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
12. Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production.
Watanabe M; Fenton RG; Wigginton JM; McCormick KL; Volker KM; Fogler WE; Roessler PG; Wiltrout RH
J Immunol; 1999 Aug; 163(4):1943-50. PubMed ID: 10438930
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-7 selectively enhances natural kill cytotoxicity mediated by the CD56bright natural killer subpopulation.
Dadmarz R; Bockstoce DC; Golub SH
Lymphokine Cytokine Res; 1994 Dec; 13(6):349-57. PubMed ID: 7535569
[TBL] [Abstract][Full Text] [Related]
14. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects.
Ugai S; Shimozato O; Yu L; Wang YQ; Kawamura K; Yamamoto H; Yamaguchi T; Saisho H; Sakiyama S; Tagawa M
Cancer Gene Ther; 2003 Oct; 10(10):771-8. PubMed ID: 14502230
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
16. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
Dorigo O; Shawler DL; Royston I; Sobol RE; Berek JS; Fakhrai H
Gynecol Oncol; 1998 Nov; 71(2):204-10. PubMed ID: 9826461
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells.
Tsuruma T; Yagihashi A; Torigoe T; Sato N; Kikuchi K; Watanabe N; Hirata K
Cell Immunol; 1998 Mar; 184(2):121-8. PubMed ID: 9630838
[TBL] [Abstract][Full Text] [Related]
18. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
19. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
20. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
